Schrödinger, Inc. announced today that it has received an additional investment of $20 million from Bill Gates.
New York, NY (PRWEB) December 13, 2012
Schrödinger, Inc. announced today that it has received an additional investment of $20 million from Bill Gates. "Schrödinger has ambitious plans for expanding their software platform that will make drug discovery significantly more productive and efficient,” said Gates. Dr. Boris Nikolic, a Scientific Advisor to Mr. Gates, will join Schrödinger’s Board of Directors.
“The success we’ve seen in our collaborations demonstrates that our computational approach can play a driving role in drug discovery," said Dr. Ramy Farid, Schrödinger’s President. "With this infusion of capital, we will be able to continue our rapid scientific progress and develop a comprehensive, enterprise-level collaboration platform that delivers Schrödinger’s powerful science to all members of a research organization."
Founded in 1990, Schrödinger is a scientific leader in chemical simulation for pharmaceutical and biotechnology research. Schrödinger’s software is used by nearly every major pharmaceutical firm worldwide as well as thousands of smaller firms and academic and government research laboratories. In recent years, Schrödinger has entered into a number of collaborations with pharmaceutical and biotech companies in which Schrödinger’s technology and expertise have had a significant impact on early-stage drug discovery projects.
Schrödinger makes significant investments in R&D, which has led to major advances in the field of computational chemistry; it has achieved breakthroughs in quantum chemistry, molecular modeling, force fields, molecular dynamics, protein structure determination, scoring, and virtual screening. The company's full product offerings range from general molecular modeling programs to a comprehensive suite of drug design software. Besides the company’s industry-leading drug discovery solutions, Schrödinger is actively developing state-of-the art simulation tools for materials research as well as enterprise software that can be deployed throughout an entire research organization. Schrödinger's methods development and applications papers have thousands of citations and are often among the most-cited scientific publications. Schrödinger's science is continually validated internally and by its users worldwide. Founded in 1990, Schrödinger has operations in the United States as well as in Europe, India, and Japan. For more information, please visit http://www.schrodinger.com.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/12/prweb10229213.htm